The Brazilian health regulatory agency, Anvisa, has prohibited the company Vita BE Cosméticos from selling its sublingual melatonin product, which was marketed with claims that lack scientific support. This decision, published in the 'Diário Oficial da União,' mandates a complete withdrawal of the product from the market, halting sales, distribution, manufacturing, and advertising activities. Anvisa expressed concerns that the ingredients in the product had not undergone necessary safety evaluations for sublingual use.

Vita BE Cosméticos, when contacted for a comment via WhatsApp, did not respond prior to the article's publication. Anvisa's action reflects a growing emphasis on consumer safety and the regulation of health-related products in Brazil. The agency specifically criticized the company's advertising practices, which claimed that the product could help regulate sleep patterns and prevent insomnia without reliable scientific backing.

Melatonin, a hormone produced naturally in the body, is known to help regulate the sleep-wake cycle. The ban on sublingual melatonin by Anvisa highlights the importance of ensuring that health products are safe and that companies do not make unverified claims about their benefits. This move could set a precedent for more rigorous regulatory practices in the wellness and supplement industry in Brazil, ensuring that consumers are receiving products that are both effective and safe.